drugset / Trial / NCT00915473
Greater Occipital Nerve Block for Migraine Prophylaxis
Phase 4
Completed
70 enrolled
Mayo Clinic
National Center for Advancing Translational Sciences (NCATS) · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
Migraine is a common neurological condition that can be disabling, particularly if chronic. Greater occipital nerve (GON) block has been utilized for decades for the treatment of migraine in the absence of a single randomized, placebo-controlled trial documenting its effectiveness. Hypothesis: Greater occipital nerve block reduces the frequency of days with moderate or severe headache in patients with episodic or chronic migraine.
Timeline
- Start
- 2009-06
- Primary completion
- 2013-01
- Completion
- 2013-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bupivacaine | Other / unclassified | 0.5 % | Other |
| Subject | Bupivacaine | Other / unclassified | 2.5 ml | Other |
| Subject | Methylprednisolone | Other / unclassified | 0.5 ml | Other |
| Subject | Methylprednisolone | Other / unclassified | 20 mg | Other |
| Comparator | Lidocaine | Other / unclassified | 0.25 ml | Other |
| Comparator | Lidocaine | Other / unclassified | 1 % | Other |